Journal Watch

S. Triple-negative breast cancer: epidemiology and management options. Drugs 2010; 70(17): 2247–58 Winther H, Jørgensen JT. Drug-diagnostic co-development in cancer. Pharmaceut Med 2010; 24(6): 363–75 Maggo SDS, Kennedy MA, Clark DWJ. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf 2010; 34(1): 1–19 Mangiacapra F, Barbato E. Individual variability of response to antiplatelet therapy is an important determinant of adverse clinical outcome. High Blood Press Cardiovasc Prev 2010; 17(3): 121–3 Vivas D, Angiolillo DJ. Platelet P2Y12 receptor inhibition: an update on clinical drug development. Am J Cardiovasc Drugs 2010; 10(4): 217–26 Rubattu S, Sciarretta S, Marchitti S, et al. NT-proANP/ANP is a determinant of vascular damage in humans. High Blood Press Cardiovasc Prev 2010; 17(3): 117–2 Wong WB, Carlson JJ, Thariani R, et al. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 2010; 28(11): 1001–13 Epstein RS, Teagarden JR. Comparative effectiveness research and personalized medicine: catalyzing or colliding? Pharmacoeconomics 2010; 28(10): 905–13 Youngster I, Arcavi L, Schechmaster R. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010; 33(9): 713–26 Monteleone P, Milano W, Petrella C, et al. Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain. J Clin Psychopharmacol 2010; 30(4): 441–5 Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirin-induced anemia and outcome of therapy: a genome-wide study of Japanese HCV patients. Gastroenterology 2010; 139(4): 1190–7 Pare L, Paez D, Salazar J, et al. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. Br J Clin Pharmacol 2010; 70(2): 268–72 Ribichini F, Graziani M, Gambaro G, et al. Early creatinine shifts predict contrast-induced nephropathy and persistent renal damage after angiography. Am J Med 2010; 123(8): 755–63 Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010; 11(11): 1057–65 International Serious Adverse Events Consortium. Unique public/private partnership expands research to identify predictive genetic markers for drug-induced serious adverse events [media release]: 2010 Sep 30 [online]. Available from: URL: http://www.saeconsortium.org/sites/default/files/SAEC%20Stage%20II%20Press%20Release%20FINAL.pdf [Accessed 2010 Dec 15] Kauf TL, Farkouh RA, Earnshaw SR, et al. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics 2010; 28(11): 1025–39 Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376(9749): 1312–9 Giusti B, Abbate R. Response to antiplatelet treatment: from genes to outcome. Lancet 2010; 376(9749): 1278–81 MacDonald N, Macleod SM. Has the time come to phase out codeine? CMAJ 2010; 182(17): 1825 Okuyama A, Nagasawa H, Suzuki K, et al. Fcgamma receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70(2): 299–304 Hiratzka LF, Bakris GL, Beckman JA, et al. 201 ACCF/AHA/AATS/ACR/ ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. Anesth Analg 2001; 111(2): 279–315 Kwon JS, Gutierrez-Barrera AM, Young D, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 2010; 28(27): 4214–2